SNIPER (ABL) -039

SNIPER (ABL) -039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 nM. IC50s are 0.54 nM, 10 nM, 12 nM, and 50 nM for ABL, cIAP1, cIAP2, XIAP, respectively[1].

Product Specifications

CAS Number

[2222354-29-0]

UNSPSC

12352005

Target

Bcr-Abl; SNIPERs

Type

Reference compound

Related Pathways

PROTAC; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sniper-abl-039.html

Solubility

10 mM in DMSO

Smiles

CC1=C(NC(C2=CN=C(NC3=CC(N4CCN(C(COCCOCCOCCOC5=CC(C(C6=CSC([C@H]7N(C([C@H](C8CCCCC8)NC([C@H](C)NC)=O)=O)CCC7)=N6)=O)=CC=C5)=O)CC4)=NC(C)=N3)S2)=O)C(Cl)=CC=C1

Molecular Formula

C54H68ClN11O9S2

Molecular Weight

1114.77

References & Citations

[1]Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108 (8) :1657-1666.